Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Initial Beneficial Ownership · 3

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Nov 19, 2026Accepted Nov 19, 2026, 3:10 PM ESTFiling CIK 1712762Accession 0001475597-26-000253
Share

Structured filing — 3

primary_doc.xml

Open full document ↗

Filing details

Report period
2026-09-22
Issuer
bioAffinity Technologies, Inc.
Issuer CIK
0001712762
Trading symbol
BIAF

Reporting owner 1

Name
HRT FINANCIAL LP
Reporting owner CIK
0001475597
Relationship
10% owner
Address
3 WORLD TRADE CENTER, 175 GREENWICH STRE, 76TH FLOOR, NEW YORK, NY, 10007

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnership
Common Stock116,782[F1]D
Table key
D
Direct

Derivative holdings

Derivative holdings · 1 reported row
SecurityConversion / exercise priceExercisableExpiresUnderlying securityUnderlying sharesOwnership
Warrant (rights to buy)3,6452022-06-222027-06-22Common Stock2.6289[F2]D
Table key
D
Direct

Footnotes

F1
The reporting person became the beneficial owner of more than 10% of the outstanding Common Stock on September 22, 2026. The amount reported represents shares of Common Stock directly held by the reporting person immediately following the transaction that resulted in such status.↩ 1
F2
Represents 1,183 warrants held at the time described in footnote (1). Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. The underlying amount is rounded to four decimal places.↩ 1

Signature 1

Signed
Adam Nunes
Date
2026-11-19

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by HRT FINANCIAL LP regarding bioAffinity Technologies, Inc.Nov 19, 2026
  2. 4 filingNov 19, 2026
  3. Other EventsNov 19, 2026
  4. Other EventsNov 17, 2026
  5. Results of Operations and Financial ConditionNov 6, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.